Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet’s disease: a randomized controlled trial

Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet’s disease: a randomized controlled trial


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: روژین فرزانه , علیرضا خبازی اسکویی , محمدصادق سلطانی زنگبار , ثمانه عباسیان , آیدا مالک مهدوی , رزا متولی خیاوی , مهدی یوسفی

کلمات کلیدی: Behc¸et’s disease; nanocurcumin; T-helper 17 cells; proinflammatory cytokines; microRNA

نشریه: 14531 , 2 , 44 , 2022

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله آیدا مالک مهدوی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های بافت همبند
کد مقاله 78344
عنوان فارسی مقاله Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet’s disease: a randomized controlled trial
عنوان لاتین مقاله Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet’s disease: a randomized controlled trial
ناشر 7
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Objective: Present research was performed to assess the effects of nanocurcumin supplementation on T-helper 17 (Th17) cells inflammatory response in patients with Behcet’s disease (BD). Methods: In this randomized double-blind, placebo-controlled trial, 36 BD subjects were randomly placed into two groups to take 80mg/day nanocurcumin or placebo for eight weeks. Disease activity, frequency of Th17 cells and expression of related parameters including retinoic acid-related orphan receptor c (RORct) transcription factor messenger RNA (mRNA), related microRNAs (miRNAs) such as miRNA-155, miRNA-181, and miRNA-326 as well as proinflammatory cytokines including interleukin (IL)-17 and IL-23 were evaluated. Results: Thirty-two patients (17 in the nanocurcumin and 15 in the placebo groups) completed the trial. Number of Th17 cells decreased significantly in the nanocurcumin group compared to baseline (p¼.012) and placebo (p¼.047). Moreover, RORct, IL-17, IL-23, miRNA-155, miRNA-181, and miRNA- 326 mRNA expression decreased significantly in the nanocurcumin group compared with baseline (p¼.004, p¼.009, p<.001, p<.001, p<.001, p<.001, respectively) and placebo (p¼.002, p¼.021, p¼.006, p¼.035, p<.001, p¼.017, respectively). Significant reductions in IL-17 and IL-23 were seen in nanocurcumin group compared with baseline (p¼.017 and p¼.015) and placebo (p¼.047 and p¼.048, respectively). Significant reduction in disease activity was observed in nanocurcumin group compared with placebo group (p¼.035). Conclusion: Nanocurcumin supplementation had favorable effects in improving inflammatory factors and disease activity in BD patients. Additional studies are warranted to suggest nanocurcumin as a safe complementary therapy in BD.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
روژین فرزانهاول
علیرضا خبازی اسکوییدوم
محمدصادق سلطانی زنگبارسوم
ثمانه عباسیانچهارم
آیدا مالک مهدویپنجم
رزا متولی خیاویششم
مهدی یوسفیهفتم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
1.pdf1400/12/272422356دانلود